

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1 of 6

Application Number	10/738,423
Filing Date	December 16, 2003
First Named Inventor	KING, et al.
Art Unit	1633
Examiner Name	Qian Janice LI
Attorney Docket Number	873-Z-US

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/qjl/	1	US- 6,475,482	11-05-2002	Bermudes, et al.	
	2	US- 5,318,900	06-07-1994	Habuka, et al.	
	3	US- 6,923,972	06-02-2005	Bermudes, et al.	
	4	US- 5,830,702	11-03-1998	Portnoy, et al	
	5	US- 6,051,237	04-18-2000	Paterson, Yvone	
	6	US- 6,863,894	03-08-2005	Bermudes, et al.	
	7	US- 6,447,784	09-10-2002	Bermudes, et al.	
	8	US- 6,685,935	02-03-2004	Pawelek, et al.	
	9	US- 2005-0249709 A1	11-10-2005	Bermudes, et al.	
	10	US- 2003-0059400 A1	03-27-2003	Szalay, et al.	
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
/qjl/	12	EP 0322237	06-28-1989	Welcome Foundation, Ltd	
	13	EP 0400958	12-02-1990	Dougan, et al.	
	14	EP 0357208	03-07-1990	Sadoff, et al.	
	15	EP 0285152	03-30-1988	Birkman, et al.	
	16	EP 0338679	10-25-1989	Sherwin, Stephen A.	
	17	EP 0564121	10-06-1993	Karapetyan, Anait	

Examiner Signature	/Q. Janice Li/ (06/12/2007)	Date Considered
--------------------	-----------------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 1B if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1448/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2

of 6

Complete if Known

Application Number	10/738,423
Filing Date	December 16, 2003
First Named Inventor	KING, et al.
Art Unit	1633
Examiner Name	Qian Janice LI
Attorney Docket Number	873-Z-US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.*	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T#
		Country Code ³ -Number ⁴ -Kind Code ⁵ (If known)				
/qjl/	18	EP 00195672	09-24-1986	Matsuhiro, Aizo		
	19	WO/1997/008955	03-13-1997	Branstrom, et al.		
	20	JP 06046890	02-22-1994	Karapetyan, Anaito		
	21	WO/1995/05835	03-02-1995	Woo, et al.	.	
↓	22	WO/1992/015689	09-17-1992	Charles, et al.		
↓	23	WO/1999/013053	03-18-1999	Bermudes, et al.		

Examiner Signature	/Q. Janice Li/ (06/12/2007)	Date Considered
-----------------------	-----------------------------	--------------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known																					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		<table border="1"> <tr> <td>Application Number</td> <td colspan="3">10/738,423</td> </tr> <tr> <td>Filing Date</td> <td colspan="3">December 16, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td colspan="3">KING, et al.</td> </tr> <tr> <td>Art Unit</td> <td colspan="3">1633</td> </tr> <tr> <td>Examiner Name</td> <td colspan="3">Qian Janice Li</td> </tr> </table>				Application Number	10/738,423			Filing Date	December 16, 2003			First Named Inventor	KING, et al.			Art Unit	1633			Examiner Name	Qian Janice Li		
		Application Number	10/738,423																						
		Filing Date	December 16, 2003																						
		First Named Inventor	KING, et al.																						
		Art Unit	1633																						
Examiner Name	Qian Janice Li																								
Sheet	3	of	6	Attorney Docket Number	873-Z-US																				

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/qjl/	11	Supplemental Partial European Search Report for Vion Pharmaceuticals, Inc., European Appl' No. 00957764.1, Filed May 3, 2002, Dated October 10, 2005		T ²
	24	European Search Report issued on May 13, 2005 for VION Pharmaceuticals, Inc., European Appl' No. EP 98946891.3		
	25	Aranda, et al., 1992, "Salmonella Typhiurium activates virulence gene transcription within acidified macrophage phagosomes," Proc. Natl. Acad. Sci USA 89:10079-10083		
	26	Bacon, et al., 1950, "The effects of biochemical mutation on the virulence of <i>Bacterium Typhosum</i> : the induction and isolation of mutants," Br. J. Exp. Path. 31:703-713		
	27	Bacon, et al., 1950, "The effects of biochemical mutation on the virulence of <i>Bacterium Typhosum</i> : the virulence of mutants," Br. J. Exp. Path. 31:714-724		
	28	Bacon, et al., 1951, "The effects of biochemical mutation on the virulence of <i>Bacterium Typhosum</i> : the loss of virulence of certain mutants," Br. J. Exp. Path. 32:85-96		
	29	Bast et al., 1975, "Antitumor activity of bacterial infection. I. Effect of <i>Listeria monocytogenes</i> on growth of a murine fibrosarcoma, II. Effect of <i>Listeria monocytogenes</i> on growth of a guinea pig hepatoma" J Natl Cancer Inst. 54(3):749-761		
	30	Bisno, et al., 1990 Classification of Streptococci," Principles and Practice of Infectious Diseases, 1518-1519		
	31	Cowan, et al., 1974, "Part B-Gram-Negative Facultative Anaerobic Rods," Determinative Biology, 8th ed., 290-340		
▼	32	Gupta, et al., 1995, "A Potent Inhibitor of Endothelial Cell Proliferation is Generated by Proteolytic Cleavage of the Chemokine Platelet Factor 4," Proc. Natl. Acad. Sci USA 92: 7799-7803		

Examiner Signature	/Q. Janice Li/ (06/12/2007)	Date Considered
--------------------	-----------------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known					
		Application Number	10/738,423				
		Filing Date	December 16, 2003				
		First Named Inventor	KING, et al.				
		Art Unit	1633				
		Examiner Name	Qian Janice Li				
Sheet	4	of	6	Attorney Docket Number			873-Z-US

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/qjl/	33	Hibbs, et al., 1976, "Role of activated macrophages in nonspecific resistance to neoplasia," J Reticuloendothel Soc 20:223-231		
	34	Hohmann, et al., 1995, "Macrophage-inducible expression of a model antigen in <i>Salmonella typhimurium</i> enhances immunogenicity," Proc Natl Acad Sci U S A 92:2904-8		
	35	Hunter et al., "Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis," J Immunol 166: 5878-81		
	36	Iruela-Arispe, et al., 1999, "Inhibition of Angiogenesis by Thrombospondin-1 is Mediated by 2 Independent Regions Within the Type 1 Repeats," Am. Hear Assoc 100: 1423-1431		
	37	Keller et al., 1990, "Resistance to a non-immunogenic tumor, induced by <i>Corynebacterium parvum</i> or <i>Listeria monocytogenes</i> , is abrogated by anti-interferon gamma," Int J Cancer 46:687-90		
	38	Koshimura, 1961, "On the streptolysin S synthetizing and anticancer activities of cell-free extract from living hemolytic streptococci," Cancer Chemother Rep. 13: 107-111		
	39	Lee, et al., "Identification of a <i>Salmonella typhimurium</i> Invasion Locus by Selection for Hyperinvasive Mutants", Proc. Nta. Acad. Sci. USA, 89: 1847-1851. 1992		
	40	Mizutani, et al., 1980, "Inhibitory effect of some intestinal bacteria on liver tumorigenesis in gnotobiotic C3H/He male mice," Cancer Letters 11:89-96		
	41	Mullen et al., "Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor," Cancer Res 54:1503-1506. 1994		
▼	42	Murata et al., 1965, "Oncolytic effect of <i>Proteus mirabilis</i> upon tumor bearing animal," Life Sci 4(10):1055-67		

Examiner Signature	/Q. Janice Li/ (06/12/2007)	Date Considered
--------------------	-----------------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete If Known**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

5

of

6

Application Number

10/738,423

Filing Date

December 16, 2003

First Named Inventor

KING, et al.

Art Unit

1633

Examiner Name

Qian Janice LI

Attorney Docket Number

873-Z-US

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/qjl/	43	North, et al., 1977, "T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites," J Exp Med 145(2):275-292	
	44	Okamoto, et al., 2002, "Enhancement of anti-tumor immunity by lipotricholic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells," Anticancer Res. 22(6A):3229-39	
	45	Okuno, et al., 1990, "Immunomodulating effect of intratumoral (IT) injection of biological response modifiers (BRM) on tumor-bearing hosts," J. Jpn Soc Cancer Ther 25(8):1543-1549. (abstract only)	
	46	Raetz, et al., 1993 "Bacterial endotoxins: extraordinary lipids that activate eucaryotic signal transduction," J Bacteriol. 175(18):5745-53	
	47	Reilly, et al., 1953, "Microbiology and cancer therapy; review," Cancer Res. 13(12):821	
	48	Romick, et al., 1996, "Aerobic and Anaerobic Metabolism of Listeria monocytogenes in Defined Glucose Medium," Applied and Environmental Microbiol 304-307	
	49	Roy, et al., "Mutations in firA, encoding the second acyltransferase in lipopolysaccharide biosynthesis, affect multiple steps in lipopolysaccharide biosynthesis," J Bacteriol. 176(6):1639-46	1994
	50	Sakamoto, et al., 1988 "Antitumor effect of normal intestinal microflora on Ehrlich ascites tumor Jpn. J. Cancer Res. 79: 109-116	
	51	Simonen, et al., 1993, "Protein secretion in Bacillus species," Microbiological Reviews 57(1):109-137	
▼	52	Tsujitani, 1998 "Endoscopic intratumoral injection of OK-432 and Langerhans' cells in patients with gastric carcinoma," Cancer 61(9):1749-53	

Examiner Signature	/Q. Janice Li/ (06/12/2007)	Date Considered	
--------------------	-----------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete If Known			
		Application Number	10/738,423		
		Filing Date	December 16, 2003		
		First Named Inventor	KING, et al.		
		Art Unit	1633		
		Examiner Name	Qian Janice LI		
Sheet	6	of	6	Attorney Docket Number	873-Z-US

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/qjl/	53	Youdim, et al., 1977, "Cooperation of immune lymphoid and reticuloendothelial cells during Listeria monocytogenes-mediated tumor immunity," Cancer Res 37(4):991-996		
	54	Youdim, et al., 1976, "Resistance to tumor growth mediated by Listeria monocytogenes. Destruction of experimental malignant melanoma by LM-activated peritoneal and lymphoid cells. J Immunol 116(3):579-584.		
	55	Youdim, et al., 1976, "Resistance to tumor growth mediated by Listeria monocytogenes: collaborative and suppressive macrophage-lymphocyte interactions in vitro," J Immunol 117(5 Pt 2):1860-5		
	56	Youdim, et al., 1974, "Nonspecific Suppression of Tumor Growth by an Immune Reaction to Listeria Monocytogenes," J Natl Cancer Inst 52(1):193-198		
	57	Cunningham, et al., 2001, "A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patient with advanced metastatic cancer" Human Gene Ther., 12: 1594-1596		
	58	Dunstan, et al., 1999, "Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. Typhimurium" Infect Immun., 67(10):5133-41		
	59	Elkins, et al., 1994, "In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice", Human Gene Ther., 5(7):809-820		
	60	Low, et al., 1998, "Disruption of the Salmonella msbB gene suppresses virulence and TNF-alpha induction yet retains tumor-targeting in vivo", Proc. Amer. Assoc. Cancer Res Annual Meeting, 39: 60 (abst 409)		
↓	61	Zinkernagel, et al., 1974 "Early appearance of sensitized lymphocytes in mice infected with Listeria monocytogenes", J Immunol, 112(2):496-501		

Examiner Signature	/Q. Janice Li/ (06/12/2007)	Date Considered
--------------------	-----------------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.